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ABSTRACT
Apolipoprotein(Apo)Eisoneofthefivemaintypesof
bloodlipoproteins(A–E).Itissynthesizedprimarilyin
the liver and brain and helps in transporting lipids
from one place to another as well as facilitates the
clearing of dietary fats, such as triglycerides, from
the blood. The ApoE gene exists in three different
forms: E2, E3 and E4. E3 is considered to be the nor-
mal form. Variants of the ApoE gene have been asso-
ciatedwithvariousdiseases.Developinganassayfor
the genotyping of ApoE variants for use both in clin-
ical and large cohort based association settings
would be extremely valuable and would require the
use of a platform that has high-throughput capabilit-
ies and is highly accurate. Here we describe an assay
forthesimultaneousgenotypingoftheApoEvariants
in a single bi-plex reaction and a single well using the
matrix-assisted laser desorption/ionization time-of-
flight(MALDI-TOF)massspectrometryandthehomo-
geneousmass-extend(hME)technology.Theassayis
robust, highly accurate and suitable for both clinical
applications and for the genotyping of large disease
cohorts.Moreover,theprevalenceofApoEvariantsin
a cohort of Caucasians from the central Wisconsin
area is outlined.
INTRODUCTION
The apolipoprotein E (ApoE) gene is located on the long (q)
arm of chromosome 19 and codes for a protein that exists in
several different forms (1). ApoE, which is synthesized prim-
arily in the liver and brain, is one of the ﬁve main types of
blood lipoproteins (A–E) and is a major component of speciﬁc
lipoproteins called very low-density lipoproteins. A major
function of very low-density lipoproteins is to remove excess
cholesterol from the blood and carry it to receptors on the
surface of liver cells for processing. ApoE helps in transport-
ing lipids from one place to another and facilitates the clearing
of dietary fats, such as triglycerides, from the blood. Main-
taining normal levels of cholesterol is essential for the pre-
vention of cardiovascular diseases, including heart attacks and
strokes. Defects in the ApoE protein could diminish its ability
to bind to the receptors, which leads to an elevated blood
cholesterol level.
The ApoE gene exists in three different forms, E2, E3 and
E4,with E3 being the mostcommon form thatis foundin more
than half the population. The ApoE E3 allele is differentiated
by a cysteine at position 112 and an arginine at position 158 in
the receptor-binding region of ApoE. The ApoE E2 allele
(Cys-112 and Cys-158) has signiﬁcantly less binding ability.
In particular, individuals with an E2/E2 combination may
clear dietary fat from their body at a slower rate and are at
a higher risk for early vascular disease and type III hyperli-
poproteinemia (2). According to a recent study, 94.4% of type
III hyperlipoproteinemia patients are homozygous for E2 (3).
Inversely, only  2% of patients homozygous for ApoE E2
develop the clinical phenotype of hyperlipoproteinemia type
III (4). It is, therefore, thought that further genetic or envir-
onmental factors must be involved in the development of the
disease. The ApoE E4 allele (Arg-112 and Arg-158) has been
linked to atherosclerosis (5). Individuals with E4/E4 genotype
are at a higher risk of developing the disease (5).
ApoE E4 has also been associated with an increased risk of
late onset of Alzheimer’s disease (developing after the age of
65). Although one copy of E4 constitutes a risk (E2/E4 or E3/
E4), two copies of E4 (E4/E4) indicate a greater risk of devel-
oping Alzheimer’s disease (6). In itself, the ApoE E4 is neither
sufﬁcient nor necessary for the development of Alzheimer’s
disease. However, ApoE genotyping can increase the speciﬁ-
city of the clinical diagnosis of Alzheimer’s disease.
Several approaches were used previously to type ApoE
alleles. The most commonly used approaches are based on
PCR–restriction fragment length polymorphism (PCR–
RFLP) (7–9). These approaches, although simple, are not
suitable for the high-throughput analysis and alleles are
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doi:10.1093/nar/gni155sometimes difﬁcult to be discerned because of the incomplete
digestion of the PCR product that is often seen with the use of
restriction enzymes. Developing an assay for use in both clin-
ical and large cohort based association settings would be
extremely valuable and would require the use of a platform
that has high-throughput capabilities and is highly accurate.
Mass spectrometry is known for its accuracy and high-
throughput potential and was used for ApoE genotyping
(10–14); however, the analysis either involved the use of
restriction enzymes, expensive Locked Nucleic Acid  probes,
and/or was not carried out in a single tube. In recent years,
matrix-assisted laser desorption/ionization time-of-ﬂight
(MADLI-TOF) mass spectrometry combined with the homo-
geneous mass-extend (hME) reaction has proven very useful
for the high-throughput mutation and single nucleotide poly-
morphism (SNP) analysis in a single tube format (15–17).
In a wide scale application of SNP genotyping utilizing
3738 SNPs from the HapMap project using the MALDI-
TOF MassARRAY system and the hME technology, Gabriel
et al. (17) reported genotyping accuracy of 99.6% at 4–7 plex
level of design. This system has also been used as a powerful
tool for genetic testing in clinical settings, as recently demon-
strated by Buyse etal.(18) by the simultaneous screening of as
many as 51 known mutations in the cystic ﬁbrosis gene, in the
molecular diagnosis of other genetic and infectious diseases
(19–24), and has the potential to become a routine method for
both laboratory and clinical applications (25–27).
We describe a novel bi-plex assay for ApoE genotyping
based on the MALDI-TOF mass spectrometry and the hME
technology, and report the distribution of the ApoE variants in
a Caucasian based cohort from central Wisconsin.
MATERIALS AND METHODS
DNA samples
Atotalof120anonymizedgenomicDNAsamplesweretested,
41 of which were cross-validated using PCR–RFLP. Seven
samples were previously tested and kindly provided to us by
the Mayo Clinic reference laboratory. The majority of the
samples were of Caucasian ancestry (108 samples), 3 of
Asians, 2 of Hispanics and 7 samples were of unknown
ethnicity (Mayo Clinic samples).
Primer design
Both the ampliﬁcation and extension primers were designed
using the Assay Designer 2.05-software from Sequenom. This
software designs the primers used for ampliﬁcation and the
base extension reactions. It also identiﬁes the appropriate ter-
mination mixture to use in the hME reaction. The ampliﬁca-
tion primers were designed with a 10mer tag sequence to
increase their mass so that they would fall outside the range
of detection of the MALDI-TOF mass spectrometry. The pri-
mers, the expected extended products, and their corresponding
masses are presented in Tables 1 and 2.
PCR for the MALDI-TOF analysis
For the bi-plex PCR ampliﬁcation, a total of 25 ng of genomic
DNAwas ampliﬁed in a 5ml reaction mixture containing0.1 U
HotStar Taq enzyme (Qiagen, Valencia, CA), 1· HotStar
buffer, 2.5 mM (total) MgCl2, 0.2 mM (each) deoxynucleotide
triphosphate, and 150 nM of each of the ApoE112 and
ApoE158 forward and reverse primers. The PCR step was
initiated with a 95 C soak for 15 min, followed by 45 cycles,
consisting of 95 C for 20 s, 56 C for 30 s, 72 C for 60 s, and a
ﬁnal extension of 3 min at 72 C.
Shrimp alkaline phosphatase (SAP)
AfterPCR,theremainingunincorporateddNTPs were dephos-
phorylated by adding 2 ml of the SAP cocktail, containing
1.53 ml of water, 0.17 ml of hME reaction buffer (Sequenom)
and 0.3 ml of SAP (Sequenom). The 384-well plate was then
sealed and placed in a thermal cycler with the following con-
ditions: 37 C for 20 min, 85 C for 5 min and 4 C indeﬁnitely.
hME reaction, nanodispensing and mass spectrometry
After the SAP treatment, a 2 ml cocktail, consisting of 1.728 ml
water; 0.2 ml hME EXTEND mixture, containing 10· buffer
and appropriate d/ddNTPs (Sequenom); 0.54 mlo f1 0mM each
extension primer mixture and 0.018 mlo f3 2U / ml Ther-
moSequenase (Sequenom) was added. After the hME cocktail
addition, the plate was again sealed and placed in a thermal
cyclerwith thefollowing program:94 Cfor2minfollowed by
55 cycles of 94 C for 5 s, 52 C for 5 s and 72 C for 5 s. The
reaction mixture was then desalted by adding 20 ml of a cat-
ionic resin mixture (6 mg), SpectroCLEAN (Sequenom). The
platewas then sealed andplaced inarotating shakerfor10min
to desalt the hME solution. Completed genotyping reactions
werespottedinnanolitervolumes ontoamatrixarrayed silicon
chip with 384 elements (Sequenom SpectroCHIP) using the
MassARRAY Nanodispenser. SpectroCHIPs were analyzed
using the Bruker Autoﬂex MALDI-TOF mass spectrometer
and the spectra were processed using the SpectroTYPER soft-
ware (Sequenom).
Table 1. ApoE extension primers and products, with their calculated masses
Primer Sequence/extension M (Da) Variation
ApoE112-UE CGGACATGGAGGACGTG 5300.5
ApoE112-C CGGACATGGAGGACGTGddC 5573.6 C
ApoE112-T CGGACATGGAGGACGTGTddC 5917.9 T
ApoE158-UE CCGATGACCTGCAGAAG 5204.4
ApoE158-C CCGATGACCTGCAGAAGddC 5477.6 C
ApoE158-T CCGATGACCTGCAGAAGTddC 5821.8 T
The extended products are underlined. ‘UE’ denotes ‘unextended.’
Table 2. Primers encompassing the ApoE112 and ApoE158 variants
Primer Sequence
ApoE112(F) 50-ACGTTGGATGCTGTCCAAGGAGCTGCAGG-30
ApoE112(R) 50-ACGTTGGATGTCGCCGCGGTACTGCACCA-30
ApoE112E 50-CGGACATGGAGGACGTG-30
ApoE158(F) 50-ACGTTGGATGTCCGCGATGCCGATGACCTG-30
ApoE158(R) 50-ACGTTGGATGCTCGCGGATGGCGCTGAGG-30
ApoE158E 50-CCGATGACCTGCAGAAGC-30
ApoE(F) 50-CTGGGCGCGGACATGGAGGAC-30
YWL-ApoE(R) 50-CACATGACCATGTCCCCTTATGCCCCGGCC
TGGTACACTGC-30
The 10mer tag sequence is italicized and underlined. The shaded primers were
used for the PCR–RFLP analysis. The YWL-tail sequence is in boldface and
underlined.
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A total of 40–50 ng of DNA was ampliﬁed in a 25 ml reaction
mixture containing a ﬁnal concentration of 1.5 mM MgCl2,1 ·
buffer (Qiagen), 200 mM of each dNTP, 0.4 mM of each of the
ApoE (F) and YWL-ApoE (R) primers (shaded rows in
Table 2), and 0.65 U HotStarTaq DNA polymerase (Qiagen).
The PCR was initiated with a 95 C soak for 15 min followed
by ampliﬁcation for 35 cycles (94 Cfor 30 s, 65 C for30 s and
72 C for 30 s), and a ﬁnal extension for 10 min at 72 C. The
YWL-tail attached to the YWL-ApoE primer was added to the
primer so that the PCR products, if required to be, can be
ﬂuorescently labeled using a ﬂuorescently labeled universal
primer that has a primer sequence exactly similar to the tail.
Nevertheless, for the validation purposes, the universal primer
was never added to the reaction mixture and the PCR product
was simply resolved on a regular 3% agarose gel as shown in
Figure 1.
A volume of 5 ml of the 209 bp PCR product was diges-
ted with 2.5 U of AFLIII or 3 U of HaeII enzymes for the
genotyping of the ApoE112 and the ApoE158 polymorphisms,
respectively, in a 25 ml reaction containing 1· NE buffer 2 and
80 mg/ml BSA. All digestions were incubated at 37 C for a
minimum of 3 h. The digested PCR product was resolved on a
3% agarose gel (NuSeive 3:1 agarose) containing 5 mlo f
10 mg/ml ethidium bromide. The gel was electrophoresed
for 55 min at 90 V and visualized under ultraviolet light.
RESULTS
The hME reaction from Sequenom is outlined in Figure 2.
Brieﬂy, the assay involves PCR ampliﬁcation, SAP treatment
to remove excess dNTPs, minisequencing using a mixture of
dideoxy and deoxy NTPs, cleanup of the extension reaction to
remove salt, spotting of the extension product into 384 Spec-
troCHIPs and the analysis of the spotted product using the
MALDI-TOF mass spectrometry. The entire procedure
requires only a single tube or well into which reagents are
dispensed in successive reaction steps. An example of the
spectra obtained from the genotyping of an individual who
iscompoundheterozygousforboththeApoE112andApoE158
polymorphisms is shown in Figure 3.
A total of 120 unique and anonymized DNA samples were
tested using the MALDI-TOF mass spectrometry. Scored
alleles were assigned a conﬁdence score based on the call
(conservative, moderate, aggressive and low probability).
More than 99% of the calls had a conservative score and
did not require manual checking. Moreover, 57 samples
were tested in duplicates in different experiments and the
results were always 100% concordant.
For assay validations, out of the 120 samples tested 7 were
of known genotypes, provided to us by Mayo Clinic, and 41
samples were genotyped using the PCR–RFLP method using
AFLIII and HaeII enzymes, which are speciﬁc for the
ApoE112 (T/C) and the ApoE158 (C/T) alleles, respectively.
Both enzymes were used previously and were validated for the
analysis of ApoE genotypes (7,28–30). This method has an
advantage over the traditional method utilizing the HhaI
enzyme that was developed by Hixson and Vernier (8) in
that the product is large enough that it can be visualized in
an agarose gel, whereas in the method of Hixson and Vernier
the HaeI fragments that are obtained are of very small size that
requires to be analyzed by acrylamide gel electrophoresis and
the use of radioactivity (8). The AFLIII cuts the ApoE112 ‘T’
allele and results in 185 bp, but does not cut the ‘C’ allele,
whereas HaeII cuts the ApoE158 ‘C’ allele and results in 165
bp, but does not cut the ‘T’ allele. An example of the PCR–
RFLP is shown in Figure 1. The data derived from the
MALDI-TOF hME assay were compared with the data derived
from the PCR–RFLP assay and the samples from Mayo Clinic.
There was 100% concordance between the two assays and
with the samples obtained from Mayo Clinic.
We have also studied the prevalence of the ApoE geno-
types in a cohort from central Wisconsin. Of the 216 chromo-
somes from the 108 Caucasian individuals from central
Wisconsin who were typed in this study, the frequency of
E2, E3 and E4 was 5.1% (11 chromosomes), 81.5% (176
chromosomes) and 13.4% (29 chromosomes), respectively.
The frequency of each of the ApoE genotypes from this
study is presented in Table 3.
Figure 1. Validation of ApoE variants using PCR–RFLP. PCR products from
representative samples were analyzed on a 3% agarose gel. From left to right,
lane1isthe1kbladdersize,standard;lanes2–4,H0001;lanes5–7,H0003;and
lanes 8–10, H0007. Uncut PCR products are loaded in lanes 2, 5 and 8. AFLIII
digestion products specific for the ApoE112 site are loaded in lanes 3, 6 and 9.
HaeII digestion products specific for the ApoE158 site are loaded in lanes 4, 7
and 10. H0001 is (T/C) at position 112 and (C/C) at position 158, resulting in a
genotype of E3/E4; H0003 is (T/T) at position 112 and (C/C) at position 158,
resultinginagenotypeofE3/E3;andH0007is(T/T)atposition112and(C/T)at
position 158, resulting in a genotype of E2/E3.
PAGE 3 OF 6 Nucleic Acids Research, 2005, Vol. 33, No. 17 e149Figure 2. Outline of the homogeneous mass-extend (hME) technology. The ApoE detection involves the amplification and detection of the two variants,
simultaneously. For simplicity, only one variant is illustrated in this diagram.
Figure 3. SimultaneousdetectionofthehMEproductsforApoE112andApoE158variantsusingMALDI-TOFmassspectrometry.AnexampleoftheMALDI-TOF
detectionisshowninthisfigure.Thex-axisshowsthemassoftheanalytesinDaltons,they-axisshowstheintensityofthepeak.TheApoE112callsareshowninopen
boxes,whereastheApoE158areshowninsolidboxes.Thepositionsofpausingpeaksthatmayresultfromincompleteextensionoftheextendingprimerareshownby
dottedlinesandaredistinguishablefromthefullyextendedproduct.Forthisassaywehavenotseenanydetectablepausingpeaks.Thegenotypecallisshowninthe
upper right of the figure.
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We have developed an efﬁcient assay for the simultaneous
genotyping of ApoE variants in a single bi-plex–single well
reaction utilizing the MassARRAY system and the hME tech-
nology. The MassARRAY system distinguishes molecules
based solely on molecular weight. This feature adds so
much importance, particularly for genetic testing, because
of the extreme high accuracy of the mass spectrometer. In
all the testing that was performed with the ApoE assay, we
found that this system is extremely accurate and highly repro-
ducible. Moreover, the direct detection of analytes solely
based on their molecular weights eliminates the need for
labeling or any separation steps. This particular feature
when combined with the high multiplexing capability, the
wide range of mass detection and the very small reaction
volumes makes this system in the long run very cost-
effective for high-throughput SNP and mutation analysis.
Another important feature of this system is that the actual
analytes can be detected directly in real-time, and therefore
if a reaction failed, the cause of failure can be easily identiﬁed
by comparing the size of the peaks of the unextended with the
extended primers. Finally, the single tube format, with all the
steps needed for PCR ampliﬁcation, phosphatase treatment,
primer extension and desalting of the extension product, per-
formed in the same well without the need for transferring the
reaction products forpuriﬁcation outside the well considerably
enhances the genotyping throughput and eliminates potential
errors associated with the transfer of reaction products.
It has been proposed that the ApoE E4 allele may act as a
thrifty allele. The exposure of ApoE E4 to the contemporary
environmental conditions (western diet and longer lifespan)
could have rendered it a susceptibility allele for coronary
artery disease and Alzheimer’s disease (31). We identiﬁed
the frequency of the ApoE alleles, and speciﬁcally ApoE
E4 allele, in a cohort from central Wisconsin. A recent
self-reported ethnic origin survey on a large cohort from
Marshﬁeld Clinic Personalized Medicine research program,
one of the largest DNA biobanks in the world with more
than 18 000 participants from central and northern Wisconsin,
has found that 76.7% of all Caucasians in central Wisconsin
are of German origin (32).
Two separate large cohort studies reported frequencies of
the ApoE alleles in Caucasians from the US and Europe.Using
a cohort of US Caucasians of non-Hispanic origin, Mastana
et al. (33) reported allele frequencies of 8, 78 and 14% for E2,
E3andE4,respectively.Recently,amorerelevantlargerstudy
that investigated ApoE allele distribution in the world, includ-
ing Germany, reported a 7.7, 77.8 and 14.5% for E2, E3 and
E4, respectively, for the German population (n ¼ 2031).
This particular study also found that the ApoE E2 frequency
ﬂuctuates with no apparent trend ranging from 2% to 14.5% in
the world (31).
Despite the relativelysmall size ofour cohort(n ¼ 108),we
observed an overall allele distribution similar to previous stud-
ies, with no signiﬁcant difference in allele distribution (Chi-
squared test, P > 0.56).
In summary, we have developed a highly accurate genotyp-
ing assay for ApoE 112 and 158 polymorphisms using the
MALDI-TOF mass spectromtry and the hME technology
that is suitable for both clinical and large-scale research
applications.
ACKNOWLEDGEMENTS
The authors would like to thank the Mayo Clinic’s Molecular
Genetics Laboratory for providing DNA samples for assay
validations and Marshfield Clinic Research Foundation for
its support through the services of Linda Weis and Alice
Stargardt in the preparation of this manuscript. Funding to
pay the Open Access publication charges for this article was
provided by Marshfield Clinic Research Foundation.
Conflict of interest statement. None declared.
REFERENCES
1. Mahley,R.W.(1988)ApolipoproteinE:cholesteroltransportproteinwith
expanding role in cell biology. Science, 240, 622–630.
2. Breslow,J.L., Zannis,V.I., SanGiacomo,T.R., Third,J.L., Tracy,T. and
Glueck,C.J.(1982)StudiesoffamilialtypeIIIhyperlipoproteinemiausing
as a genetic marker the apoE phenotype E2/2. J. Lipid Res., 23,
1224–1235.
3. Feussner,G., Feussner,V., Hoffmann,M.M., Lohrmann,J., Wieland,H.
and Marz,W. (1998) Molecular basis of type III hyperlipoproteinemia in
Germany. Hum. Mutat., 11, 417–423.
4. Civeira,F., Pocovi,M., Cenarro,A., Casao,E., Vilella,E., Joven,J.,
Gonzalez,J.,Garcia-Otin,A.L.andOrdovas,J.M.(1996)ApoEvariantsin
patients with type III hyperlipoproteinemia. Atherosclerosis, 127,
273–282.
5. Davignon,J., Gregg,R.E. and Sing,C.F. (1988) Apolipoprotein E
polymorphism and atherosclerosis. Arteriosclerosis, 8, 1–21.
6. Corder,E.H., Saunders,A.M., Strittmatter,W.J., Schmechel,D.E.,
Gaskell,P.C., Small,G.W., Roses,A.D., Haines,J.L. and Pericak-
Vance,M.A. (1993) Gene dose of apolipoprotein E type 4 allele and the
risk ofAlzheimer’sdisease in lateonsetfamilies.Science,261, 921–923.
7. Chapman,J.,Estupinan,J.,Asherov,A.andGoldfarb,L.G.(1996)Asimple
and efficient method for apolipoprotein E genotype determination.
Neurology, 46, 1484–1485.
8. Hixson,J.E. and Vernier,D.T. (1990) Restriction isotyping of human
apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid
Res., 31, 545–548.
9. Addya,K., Wang,Y.L. and Leonard,D.G. (1997) Optimization of
apolipoprotein E genotyping. Mol. Diagn., 2, 271–276.
10. Little,D.P., Braun,A., Darnhofer-Demar,B. and Koster,H. (1997)
Identification of apolipoprotein E polymorphisms using temperature
cycled primer oligo base extension and mass spectrometry. Eur. J. Clin.
Chem. Clin. Biochem., 35, 545–548.
11. Srinivasan,J.R., Kachman,M.T., Killeen,A.A., Akel,N., Siemieniak,D.
and Lubman,D.M. (1998) Genotyping of apolipoprotein E by
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Rapid Commun. Mass Spectrom., 12, 1045–1050.
12. Komiyama,M., Ye,S., Liang,X., Yamamoto,Y., Tomita,T., Zhou,J.M.
and Aburatani,H. (2003) PNA for one-base differentiating protection of
DNA from nuclease and its use for SNPs detection. J. Am. Chem. Soc.,
125, 3758–3762.
13. Ren,B., Zhou,J.M. and Komiyama,M. (2004) Straightforward detection
of SNPs in double-stranded DNA by using exonuclease III/nuclease
S1/PNA system. Nucleic Acids Res., 32, e42.
Table 3. Genotypes and frequency of ApoE variants
Call ApoE112 ApoE158 Frequency (%)
E2, E2 TT TT 0.9
E3, E3 TT CC 66.7
E4, E4 CC CC 0.9
E2, E3 TT TC 6.5
E2, E4 TC TC 1.9
E3, E4 TC CC 23.1
PAGE 5 OF 6 Nucleic Acids Research, 2005, Vol. 33, No. 17 e14914. Jacobsen,N., Bentzen,J., Meldgaard,M., Jakobsen,M.H., Fenger,M.,
Kauppinen,S. and Skouv,J. (2002) LNA-enhanced detection of single
nucleotide polymorphisms in the apolipoprotein E. Nucleic Acids Res.,
30, e100.
15. Jurinke,C., van den Boom,D., Cantor,C.R. and Koster,H. (2002)
Automated genotyping using the DNA MassArray technology.
Methods Mol. Biol., 187, 179–192.
16. Bray,M.S., Boerwinkle,E. and Doris,P.A. (2001) High-throughput
multiplex SNP genotyping with MALDI-TOF mass spectrometry:
practice, problems and promise. Hum. Mutat., 17, 296–304.
17. Gabriel,S.B., Schaffner,S.F., Nguyen,H., Moore,J.M., Roy,J.,
Blumenstiel,B., Higgins,J., DeFelice,M., Lochner,A., Faggart,M. et al.
(2002) The structure of haplotype blocks in the human genome. Science,
296, 2225–2229.
18. Buyse,I.M., McCarthy,S.E., Lurix,P., Pace,R.P., Vo,D., Bartlett,G.A.,
Schmitt,E.S., Ward,P.A., Oermann,C., Eng,C.M. and Roa,B.B. (2004)
Use of MALDI-TOF mass spectrometry in a 51-mutation test for cystic
fibrosis: evidence that 3199del6 is a disease-causing mutation. Genet.
Med., 6, 426–430.
19. Hung,K., Sun,X., Ding,H., Kalafatis,M., Simioni,P. and Guo,B. (2002)
Amatrix-assistedlaserdesorption/ionizationtime-of-flightbasedmethod
for screening the 1691G(A mutation in the factor V gene. Blood Coagul.
Fibrinolysis, 13, 117–122.
20. Humeny,A., Bonk,T., Berkholz,A., Wildt,L. and Becker,C.M. (2001)
Genotyping of thrombotic risk factors by MALDI-TOF mass
spectrometry. Clin. Biochem., 34, 531–536.
21. Bonk,T., Humeny,A., Sutter,C., Gebert,J., von Knebel Doeberitz,M. and
Becker,C.M. (2002) Molecular diagnosis of familial adenomatous
polyposis(FAP):genotypingofadenomatouspolyposiscoli(APC)alleles
by MALDI-TOF mass spectrometry. Clin. Biochem., 35, 87–92.
22. Meyer,K., Fredriksen,A. and Ueland,P.M. (2004) High-level multiplex
genotyping of polymorphisms involved in folate or homocysteine
metabolism by matrix-assisted laser desorption/ionization mass
spectrometry. Clin. Chem., 50, 391–402.
23. Harksen,A.,Ueland,P.M.,Refsum,H.andMeyer,K.(1999)Fourcommon
mutations of the cystathionine beta-synthase gene detected by multiplex
PCR and matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Clin. Chem., 45, 1157–1161.
24. Ilina,E.N., Malakhova,M.V., Generozov,E.V., Nikolaev,E.N. and
Govorun,V.M.(2005)Matrix-assistedlaserdesorptionionization-timeof
flight (mass spectrometry) for hepatitis C virus genotyping. J. Clin.
Microbiol., 43, 2810–2815.
25. Marvin,L.F., Roberts,M.A. and Fay,L.B. (2003) Matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry in clinical
chemistry. Clin. Chim. Acta, 337, 11–21.
26. Corona,G. and Toffoli,G. (2004) High throughput screening of
genetic polymorphisms by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry. Comb. Chem. High Throughput
Screen., 7, 707–725.
27. Tost,J.andGut,I.G.(2005)Genotypingsinglenucleotidepolymorphisms
by MALDI mass spectrometry in clinical applications. Clin. Biochem.,
38, 335–350.
28. Hoffmann,M.M., Scharnagl,H., Koster,W., Winkler,K., Wieland,H. and
Marz,W. (2001) Apolipoprotein E1 Baden (Arg(180)!Cys). A new
apolipoprotein E variant associated with hypertriglyceridemia.
Clin. Chim. Acta, 303, 41–48.
29. Francoual,J., Audibert,F., Trioche,P., Chalas,J., Capel,L.,
Lindenbaum,A.,Labrune,P.andFrydman,R.(2002)Isapolymorphismof
the apolipoprotein E gene associated with preeclampsia? Hypertens.
Pregnancy, 21, 127–133.
30. Zivelin,A., Rosenberg,N., Peretz,H., Amit,Y., Kornbrot,N. and
Seligsohn,U. (1997) Improved method for genotyping apolipoprotein E
polymorphisms by a PCR-based assay simultaneously utilizing two
distinct restriction enzymes. Clin. Chem., 43, 1657–1659.
31. Corbo,R.M. and Scacchi,R. (1999) Apolipoprotein E (APOE) allele
distribution in the world. Is APOE?4 a ‘thrifty’ allele? Ann. Hum.
Genet., 63, 301–310.
32. McCarty,C.A., Wilke,R.A., Giampietro,P.F., Wesbrook,S.D. and
Caldwell,M.D. (2005) Marshfield Clinic Personalized Medicine
Research Project (PMRP): design, methods and recruitment
for a large population-based biobank. Personalized Med., 2,
49–79.
33. Mastana,S.S., Calderon,R., Pena,J., Reddy,P.H. and Papiha,S.S. (1998)
Anthropology of the apoplipoprotein E (apo E) gene: low frequency of
apo E4 allele in Basques and in tribal (Baiga) populations of India.
Ann. Hum. Biol., 25, 137–143.
e149 Nucleic Acids Research, 2005, Vol. 33, No. 17 PAGE 6 OF 6